TCGA-BH-A5IZ-01A-11R-A27Q-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 19
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- G2M_CHECKPOINT+0.470
- MYC_TARGETS_V2+0.470
- MYC_TARGETS_V1+0.390
- UV_RESPONSE_UP+0.300
- TNFA_SIGNALING_VIA_NFKB+0.280
- GLYCOLYSIS+0.270
- MITOTIC_SPINDLE+0.230
- IL6_JAK_STAT3_SIGNALING+0.210
- NOTCH_SIGNALING+0.190
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.400
- FATTY_ACID_METABOLISM-0.260
- BILE_ACID_METABOLISM-0.220
- INTERFERON_GAMMA_RESPONSE-0.190
- UV_RESPONSE_DN-0.150
- PANCREAS_BETA_CELLS-0.140
- ADIPOGENESIS-0.130
- TGF_BETA_SIGNALING-0.120
- OXIDATIVE_PHOSPHORYLATION-0.100
- PROTEIN_SECRETION-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0RE-01A-11R-A056-07 | — | E | 0.822 |
| 2 | TCGA-A1-A0SP-01A-11R-A084-07 | — | E | 0.818 |
| 3 | TCGA-EW-A1P8-01A-11R-A144-07 | — | E | 0.793 |
| 4 | SRR35579844 | — | E | 0.790 |
| 5 | TCGA-A8-A07O-01A-11R-A00Z-07 | — | E | 0.789 |
| 6 | TCGA-E2-A1LL-01A-11R-A144-07 | — | C | 0.775 |
| 7 | MNG151 | — | — | 0.775 |
| 8 | TCGA-A2-A0D2-01A-21R-A034-07 | — | E | 0.766 |
| 9 | TCGA-AR-A1AY-01A-21R-A12P-07 | — | E | 0.766 |
| 10 | SRR8613795 | — | E | 0.764 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.280 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.140 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.120 | Inavolisib | — uncovered |
| COMPLEMENT | 0.110 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |